# Alkermes plc.

Summary updated: 2026-10-02T15:29:58.257189Z
Canonical: https://finbar.com/research/companies/alkermes-plc

## Overview

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions. Its products address alcohol and opioid dependence, schizophrenia, and bipolar I disorder; its portfolio includes VIVITROL, ARISTADA, ARISTADA INITIO, and LYBALVI. The company also earns manufacturing and royalty revenue from products commercialized by licensees. Its stated mission emphasizes applying neuroscience expertise with “great science with deep compassion” to make an impact for patients, families, and communities. [1](https://app.finbar.com/go?id=P116209369)[2](https://app.finbar.com/go?id=P68271417)[3](https://www.alkermes.com/about-us)

Alkermes is headquartered in Ireland, with a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. As of February 20, 2026, it had approximately 2,050 full-time employees, about 1,950 in the United States and 100 in Ireland. For the year ended December 31, 2025, it reported total revenue of $1.476 billion. [1](https://app.finbar.com/go?id=P116209369)[4](https://app.finbar.com/go?id=P27862801)[5](https://app.finbar.com/go?id=T11844588)
[1](https://app.finbar.com/go?id=P116209369)[2](https://app.finbar.com/go?id=P68271417)[3](https://www.alkermes.com/about-us)[4](https://app.finbar.com/go?id=P27862801)[5](https://app.finbar.com/go?id=T11844588)[3](https://www.alkermes.com/about-us)

## Products & services

Alkermes’ U.S. proprietary products include VIVITROL, an extended-release naltrexone injection given once monthly for alcohol dependence and prevention of opioid-dependence relapse after detoxification. The company also markets ARISTADA, an extended-release aripiprazole injection for schizophrenia, and ARISTADA INITIO, an initiation formulation used with oral aripiprazole when starting ARISTADA. ARISTADA is available in monthly, six-weekly and every-two-month dosing regimens; INITIO uses LINKERX and NANOCRYSTAL technologies to support faster dissolution and initiation of treatment. Alkermes manufactures and commercializes these products in the U.S. [6](https://app.finbar.com/go?id=P143866343)[7](https://app.finbar.com/go?id=P143866345)

LYBALVI is a once-daily oral combination of olanzapine and samidorphan for adults with schizophrenia or bipolar I disorder. Its available tablets contain 10 mg samidorphan with 5, 10, 15 or 20 mg olanzapine. LUMRYZ is an extended-release sodium oxybate oral suspension taken once at bedtime for cataplexy or excessive daytime sleepiness associated with narcolepsy; it is approved for adults and patients aged seven and older. LUMRYZ uses a version of Alkermes’ MICROPUMP technology, is third-party manufactured, and is distributed through an FDA-required REMS. [8](https://app.finbar.com/go?id=P143866352)[9](https://app.finbar.com/go?id=P143866349)[10](https://app.finbar.com/go?id=P143866350)

In FY2025, proprietary net sales were $1,184.6 million: VIVITROL contributed $467.9 million (39.5%), ARISTADA and ARISTADA INITIO together $370.0 million (31.2%), and LYBALVI $346.7 million (29.3%). In the six months ended June 30, 2026, proprietary net sales were $749.838 million, including $236.888 million from VIVITROL, $190.543 million from ARISTADA and ARISTADA INITIO, $186.343 million from LYBALVI, and $136.064 million from LUMRYZ. [11](https://app.finbar.com/go?id=T2946407)[12](https://app.finbar.com/go?id=T16461942)

Alkermes also licenses proprietary technologies used in certain Janssen long-acting injectable products, including INVEGA SUSTENNA, INVEGA TRINZA and INVEGA HAFYERA, and receives technology-related royalties. These are licensed products rather than Alkermes-marketed products. [13](https://app.finbar.com/go?id=P143866179)
[6](https://app.finbar.com/go?id=P143866343)[7](https://app.finbar.com/go?id=P143866345)[8](https://app.finbar.com/go?id=P143866352)[9](https://app.finbar.com/go?id=P143866349)[10](https://app.finbar.com/go?id=P143866350)[11](https://app.finbar.com/go?id=T2946407)[12](https://app.finbar.com/go?id=T16461942)[13](https://app.finbar.com/go?id=P143866179)

## Geographic presence

Alkermes plc is incorporated in Ireland and has its principal executive offices in Dublin. Its geographic operating footprint includes manufacturing operations in the United States and Ireland; its major owned manufacturing facility is in Wilmington, Ohio. The company also identifies a Waltham, Massachusetts site. [14](https://app.finbar.com/go?id=P17794922)[15](https://app.finbar.com/go?id=P68453244)[16](https://app.finbar.com/go?id=P79268760)[17](https://app.finbar.com/go?id=P112169475)[18](https://www.alkermes.com/about-us/locations-waltham-massachusetts)

Alkermes’ proprietary-product sales are reported for the U.S., while royalty revenue can reflect sales in licensed markets outside the U.S.; its RISPERDAL CONSTA license is worldwide. The reviewed disclosures do not provide revenue percentages by country or region, or a full employee distribution by geography. [19](https://app.finbar.com/go?id=T16461966)[20](https://app.finbar.com/go?id=P64889551)
[14](https://app.finbar.com/go?id=P17794922)[15](https://app.finbar.com/go?id=P68453244)[16](https://app.finbar.com/go?id=P79268760)[17](https://app.finbar.com/go?id=P112169475)[18](https://www.alkermes.com/about-us/locations-waltham-massachusetts)[19](https://app.finbar.com/go?id=T16461966)[20](https://app.finbar.com/go?id=P64889551)[18](https://www.alkermes.com/about-us/locations-waltham-massachusetts)

## Business segments

Alkermes reports one operating and reportable segment, managed on a consolidated basis. Its focus is developing, manufacturing and commercializing medicines for complex, difficult-to-treat psychiatric and neurological disorders; it does not report individual products as separate segments. [21](https://app.finbar.com/go?id=P116022909)[22](https://app.finbar.com/go?id=P143866086)

The single segment represented 100% of revenue: $1,475.9 million in FY2025 and $888.9 million in the first half of 2026. [23](https://app.finbar.com/go?id=T8476620)[24](https://app.finbar.com/go?id=T16461965)

As an alternative view—not an official segment breakdown—FY2025 revenue by product category included VIVITROL (31.7% of total), ARISTADA (25.1%), LYBALVI (23.5%), VUMERITY (8.8%), partnered long-acting antipsychotics (8.8%) and legacy products (2.1%). [23](https://app.finbar.com/go?id=T8476620)
[21](https://app.finbar.com/go?id=P116022909)[22](https://app.finbar.com/go?id=P143866086)[23](https://app.finbar.com/go?id=T8476620)[24](https://app.finbar.com/go?id=T16461965)

## Company history

Alkermes’ corporate roots date to 1987, when Alkermes, Inc. was organized. A key early commercial milestone came in 2003, when Risperdal Consta, which uses the company’s Medisorb technology, received U.S. FDA approval and launched in the United States. In 2006, the FDA approved VIVITROL for alcohol dependence; in 2010, it approved the medicine to prevent relapse to opioid dependence after detoxification. [25](https://www.sec.gov/Archives/edgar/data/874663/000095013505003306/b55366aie10vk.htm)[26](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-risperdal-consta-launch-united-states-its)[27](https://investor.alkermes.com/news-releases/news-release-details/alkermes-and-cephalon-receive-fda-approval-vivitroltm-treatment/)[28](https://investor.alkermes.com/news-releases/news-release-details/vivitrolr-and-value-medication-assisted-treatment-opioid)

In 2011, Alkermes combined with Elan’s Drug Technologies business, establishing Alkermes plc and its Irish corporate operations. The company expanded its proprietary medicines with FDA approval of ARISTADA for schizophrenia in 2015 and LYBALVI for schizophrenia and bipolar I disorder in 2021. In 2023, it completed the separation of its oncology business into Mural Oncology plc. Alkermes completed its acquisition of Avadel Pharmaceuticals in February 2026, and Blair Jackson succeeded Richard Pops as CEO on August 1, 2026. [29](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-launches-corporate-operations-ireland/)[30](https://investor.alkermes.com/news-releases/news-release-details/fda-approves-aristadatm-treatment-schizophrenia/)[31](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvi-treatment)[32](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-financial-results-fourth-quarter-and-year-3)[33](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc)[34](https://www.biospace.com/press-releases/alkermes-plc-announces-ceo-succession-plan)
[25](https://www.sec.gov/Archives/edgar/data/874663/000095013505003306/b55366aie10vk.htm)[26](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-risperdal-consta-launch-united-states-its)[27](https://investor.alkermes.com/news-releases/news-release-details/alkermes-and-cephalon-receive-fda-approval-vivitroltm-treatment/)[28](https://investor.alkermes.com/news-releases/news-release-details/vivitrolr-and-value-medication-assisted-treatment-opioid)[29](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-launches-corporate-operations-ireland/)[30](https://investor.alkermes.com/news-releases/news-release-details/fda-approves-aristadatm-treatment-schizophrenia/)[31](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvi-treatment)[32](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-financial-results-fourth-quarter-and-year-3)[33](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc)[34](https://www.biospace.com/press-releases/alkermes-plc-announces-ceo-succession-plan)[25](https://www.sec.gov/Archives/edgar/data/874663/000095013505003306/b55366aie10vk.htm)[26](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-risperdal-consta-launch-united-states-its)[27](https://investor.alkermes.com/news-releases/news-release-details/alkermes-and-cephalon-receive-fda-approval-vivitroltm-treatment/)[28](https://investor.alkermes.com/news-releases/news-release-details/vivitrolr-and-value-medication-assisted-treatment-opioid)[29](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-launches-corporate-operations-ireland/)[30](https://investor.alkermes.com/news-releases/news-release-details/fda-approves-aristadatm-treatment-schizophrenia/)[31](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvi-treatment)[32](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-financial-results-fourth-quarter-and-year-3)[33](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc)[34](https://www.biospace.com/press-releases/alkermes-plc-announces-ceo-succession-plan)

## Sources

1. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P116209369)
2. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P68271417)
3. [www.alkermes.com](https://www.alkermes.com/about-us)
4. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P27862801)
5. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T11844588)
6. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866343)
7. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866345)
8. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866352)
9. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866349)
10. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866350)
11. [Alkermes plc. — Press release (2025 Y)](https://app.finbar.com/go?id=T2946407)
12. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16461942)
13. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866179)
14. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P17794922)
15. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P68453244)
16. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P79268760)
17. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P112169475)
18. [www.alkermes.com](https://www.alkermes.com/about-us/locations-waltham-massachusetts)
19. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16461966)
20. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P64889551)
21. [Alkermes plc. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P116022909)
22. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P143866086)
23. [Alkermes plc. — Press release (2025 Y)](https://app.finbar.com/go?id=T8476620)
24. [Alkermes plc. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16461965)
25. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/874663/000095013505003306/b55366aie10vk.htm)
26. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-risperdal-consta-launch-united-states-its)
27. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-and-cephalon-receive-fda-approval-vivitroltm-treatment/)
28. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/vivitrolr-and-value-medication-assisted-treatment-opioid)
29. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-launches-corporate-operations-ireland/)
30. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/fda-approves-aristadatm-treatment-schizophrenia/)
31. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-approval-lybalvi-treatment)
32. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-reports-financial-results-fourth-quarter-and-year-3)
33. [investor.alkermes.com](https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc)
34. [www.biospace.com](https://www.biospace.com/press-releases/alkermes-plc-announces-ceo-succession-plan)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.